Page 24 - பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா பெரல்மேன் பள்ளி மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Race Correction May Lead to Underdiagnosis of Lung Disease
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
Wuhan lab leak: Why scientists are interested in this Covid origin theory
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
How a well-meaning U.S. government database fuels dangerous vaccine misinformation
By Melissa Goldin, John Gregory, and Kendrick McDonald
On 5/25/21 at 12:01 AM EDT
Anna Shvets/Pexels
On April 30, 2021, the website Natural News which NewsGuard has rated Red, meaning generally unreliable published a story reporting the death of a 2-year-old who in late February had received the second dose of a Pfizer-BioNTech COVID-19 vaccine during the companies clinical trials for children. The only problem? Children under 5 did not begin receiving shots until April, according to a press releaseon the Pfizer website.
Natural News picked up the false claim from a familiar source of pandemic misinformation: Red-rated website Great Game India, which in January 2020 also spread a different falsehood that the COVID-19 virus was stolen from a Canadian lab.
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress Corbus Pharmaceuticals Holdings, Inc. Norwood, Massachusetts, UNITED STATES
Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2021 Virtual Congress that will be taking place June 2-5, 2021.
Details of the presentations are as follows:
Presentation Title
: Phase 3 Trial of Lenabasum, a CB2 Agonist, for the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Session: Progress in myositis and scleroderma research - I
vimarsana © 2020. All Rights Reserved.